Cubist Cidecin review extended
Executive Summary
FDA extends June 20 priority review action date for Cubist's Cidecin (daptomycin) injection three months to Sept. 20. The extension follows reformatting of data sets, which FDA classified as a "major amendment." The company still expects to launch the product for treatment of complicated skin and skin structure infections by the end of 2003...
You may also be interested in...
Cubicin clears FDA
Cubist's Cubicin, formerly Cidecin (daptomycin for injection) is approved Sept. 12 for treatment of complicated skin and skin structure infections. An FDA "Talk Paper" notes it is the first cyclic lipopeptide antibacterial agent. Cubicin's priority action review date of June 20 had been extended three months after reformatting of data sets (1"The Pink Sheet" June 23, 2003, In Brief)...
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.